EPAS1 and neoplasm: Since ATXN3 promotes PD-L1 expression through STAT3 and HIF-2α, it will be interesting to test whether ATXN3 inhibition synergizes with STAT3- and HIF-2α–specific inhibitors in suppressing tumor growth, which could provide useful insights in translational studies.